^
Association details:
Biomarker:TGFB1 elevation
Cancer:Neuroendocrine Tumor
Drug:everolimus (mTOR inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

1121P - Prognostic value of soluble transforming growth factor-ß and soluble programmed death-ligand 1 in patients with non-functioning neuroendocrine tumors or pheochromocytomas/paragangliomas

Published date:
09/13/2021
Excerpt:
The study population consisted of 34 patients who received everolimus as a systemic treatment for non-functioning NETs, pheochromocytoma, or extra-adrenal paragangliomas....Patients with low sTGF-β level (<26.12 ng/mL) at baseline showed better progression-free survival (PFS) than those with high sTGF-β level (22.73 months vs. 12.97 months, p=0.019). Similarly, patients with low sPD-L1 level (<6.65 ng/mL) at baseline tended to have longer PFS than patients with high sPD-L1 level (18.97 months vs. 7.37 months, p=0.095). In multivariate analysis, the prognostic value of baseline sTGF-β for PFS retained its significance in patients with non-functioning NET (Hazard ratio 6.04, 95% confidential interval 1.13-32.38, p=0.036).